Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.61), $0.25 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $161.26 million versus the consensus estimate of $153.04 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.